Embecta's (EMBC) Hold (C-) Rating Reaffirmed at Weiss Ratings

Key Points

• Embecta's stock has been reaffirmed with a "hold (C-)" rating by Weiss Ratings, while average analyst ratings reflect a consensus "hold" with a target price of $19.00.
• The company reported an EPS of $1.12 for the last quarter, exceeding expectations and showing an 8.4% increase in revenue compared to the previous year.
• Approximately 93.83% of Embecta's stock is owned by institutional investors, indicating strong institutional interest in the company.

Embecta (NASDAQ:EMBC - Get Free Report)'s stock had its "hold (c-)" rating reiterated by equities research analysts at Weiss Ratings in a report released on Friday,Weiss Ratings reports.

Several other equities research analysts have also issued reports on EMBC. BTIG Research reaffirmed a "buy" rating and set a $25.00 price target on shares of Embecta in a report on Friday, September 5th. Wall Street Zen raised shares of Embecta from a "buy" rating to a "strong-buy" rating in a report on Saturday, August 16th. Zacks Research lowered shares of Embecta from a "strong-buy" rating to a "hold" rating in a report on Tuesday, October 7th. Finally, Mizuho decreased their price target on shares of Embecta from $13.00 to $12.00 and set a "neutral" rating on the stock in a report on Wednesday, July 16th. One investment analyst has rated the stock with a Buy rating and four have given a Hold rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Hold" and a consensus price target of $19.00.

Embecta Stock Up 1.3%

EMBC stock opened at $14.33 on Friday. Embecta has a 12 month low of $9.20 and a 12 month high of $21.48. The firm has a market cap of $838.16 million, a P/E ratio of 10.02, a P/E/G ratio of 0.78 and a beta of 1.10. The company's 50-day moving average price is $14.29 and its two-hundred day moving average price is $12.18.

Embecta (NASDAQ:EMBC - Get Free Report) last released its earnings results on Friday, August 8th. The company reported $1.12 EPS for the quarter, beating the consensus estimate of $0.77 by $0.35. Embecta had a net margin of 7.58% and a negative return on equity of 23.40%. The firm had revenue of $295.50 million for the quarter, compared to analyst estimates of $278.15 million. During the same period last year, the firm earned $0.74 EPS. The business's quarterly revenue was up 8.4% compared to the same quarter last year. Embecta has set its FY 2025 guidance at 2.900-2.950 EPS. Equities analysts predict that Embecta will post 2.85 EPS for the current year.

Institutional Investors Weigh In On Embecta

Several hedge funds have recently added to or reduced their stakes in the business. Oppenheimer Asset Management Inc. boosted its position in Embecta by 9.0% during the 1st quarter. Oppenheimer Asset Management Inc. now owns 11,004 shares of the company's stock worth $140,000 after buying an additional 907 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS boosted its position in Embecta by 7.9% during the 2nd quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 15,005 shares of the company's stock worth $145,000 after buying an additional 1,093 shares during the period. The Manufacturers Life Insurance Company boosted its position in Embecta by 5.4% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 21,589 shares of the company's stock worth $209,000 after buying an additional 1,110 shares during the period. CWM LLC boosted its position in Embecta by 16.0% during the 2nd quarter. CWM LLC now owns 8,080 shares of the company's stock worth $78,000 after buying an additional 1,115 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in Embecta by 2.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,323 shares of the company's stock worth $629,000 after buying an additional 1,159 shares during the period. 93.83% of the stock is currently owned by institutional investors and hedge funds.

About Embecta

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.